Last deal

$30M

Amount

Post-IPO Debt

Stage

01.06.2016

Date

2

all rounds

$57.01M

Total amount

date founded

Financing round

General

About Company
Cardiome Pharma Corp. develops and sells therapies for heart disease patients.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1986

founders

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

The specialty biopharmaceutical company, Cardiome Pharma Corp., focuses on discovering, developing, and commercializing new treatments for heart disease. Their flagship product, BRINAVESSTM, is approved in Europe and other regions for rapidly converting recent onset atrial fibrillation to sinus rhythm in adults.
Contacts

Phone number

Social url

Similar Companies
1000
Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical develops novel pharmaceutical solutions for large unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

Melville, NY, USA

total rounds

1
Achillion Pharmaceuticals

Achillion Pharmaceuticals

Achillion Pharmaceuticals develops small molecule drugs to help patients with complement system diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

Blue Bell, PA, USA

total rounds

6

total raised

$468.71M
Cardior Pharmaceuticals

Cardior Pharmaceuticals

Cardior Pharmaceuticals develops innovative RNA-based therapeutics to prevent and treat heart disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Hanover, Germany

total rounds

3

total raised

$75.16M
Mezzion

Mezzion

Mezzion Pharmaceuticals develops hope for rare disease patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Pharmaceuticals, Biotechnology

Location

Deerfield, IL, USA

total rounds

1

total raised

$40M
M&A Details
1

Acquired by

Cipher Pharmaceuticals

announced date

28.03.2018

price

$25.5M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$57.01M

Money Raised

Their latest funding was raised on 01.06.2016. Their latest investor CRG. Their latest round Post-IPO Debt

Date 
Funding Round 
Investors 
Money Raised 
Lead 
01.06.2016
1
$30M
11.03.2014
$27.01M
Local Amount - CAD 30M
CRG

CRG

CRG is a healthcare-focused investment firm that provides customized financing solutions.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Houston, TX, USA

count Of Investments

56

count Of Exists

16
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Debt
CRG

CRG

CRG is a healthcare-focused investment firm that provides customized financing solutions.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Houston, TX, USA

count Of Investments

56

count Of Exists

16

People

Founders
1
Alan Ezrin
Alan Ezrin

Alan Ezrin

Alan Ezrin is the President & CEO NxDevelopment Corp.

current job

NX Development Corp.
NX Development Corp.

organization founded

3

Alan Ezrin

Employee Profiles
17

Karen Lo

Senior project manager

Michelle Duncan

Manager, technical services and cmc operations

William Hunter

CEO

Daniel Bednarik

Daniel Bednarik

Director, Genomics & Bioinformatics; Head, Infectious Diseases Program

Activity

Recent News
0